BIONOMICS LIMITED - Announcements

Currently unlisted. Add to my watchlist

Bionomics Limited (Bionomics) is an Australia-bases clinical-stage biopharmaceutical... Bionomics Limited (Bionomics) is an Australia-bases clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of novel, ion channel targeting drug candidates designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders. The Company operates in drug development segment in Australia. The Company is advancing its lead drug candidate, BNC210, which is an oral, proprietary, selective negative allosteric modulator of the a7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). The Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

BNO	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/19	344.66KB	Share
BNO	S&P DJI Announces March 2019 Quarterly Rebalance	PRICE SENSITIVE	08/03/19	175.31KB	Share
BNO	Further Analysis of Phase 2 PTSD Trial Results Presentation	PRICE SENSITIVE	18/02/19	690.3KB	Share
BNO	Further Analysis of Phase 2 PTSD Results	PRICE SENSITIVE	18/02/19	136.22KB	Share
BNO	Half Yearly Report and Accounts	PRICE SENSITIVE	15/02/19	497.57KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/19	369.07KB	Share
BNO	BNC105 Clinical Trial In Combination With Nivolumab	PRICE SENSITIVE	04/01/19	142.39KB	Share
BNO	Bionomics Receives $650k Licensing Revenue from CTx	PRICE SENSITIVE	21/12/18	77.03KB	Share
BNO	Bionomics Receives Over $6.5m R&D Tax Incentive Refund	PRICE SENSITIVE	11/12/18	106.51KB	Share
BNO	CEO 2018 AGM Presentation	PRICE SENSITIVE	14/11/18	1.7MB	Share
BNO	Executive Chairman 2018 AGM Presentation	PRICE SENSITIVE	14/11/18	532.94KB	Share
BNO	FUND RAISING UPDATE	PRICE SENSITIVE	14/11/18	121.77KB	Share
BNO	Trading Halt	PRICE SENSITIVE	12/11/18	299.32KB	Share
BNO	Recapitalisation by major US-based biotechnology investor	PRICE SENSITIVE	09/11/18	101.83KB	Share
BNO	Leadership Changes and Strategic Review	PRICE SENSITIVE	09/11/18	99.71KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	29/10/18	264.69KB	Share
BNO	Bionomics' PTSD Trail Results Presentation	PRICE SENSITIVE	02/10/18	948.2KB	Share
BNO	Bionomics' PTSD Trial Results	PRICE SENSITIVE	02/10/18	120.84KB	Share
BNO	Trading Halt	PRICE SENSITIVE	28/09/18	135.47KB	Share
BNO	Bionomics 2017/2018 Preliminary Final Results	PRICE SENSITIVE	16/08/18	197.44KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	20/07/18	258.5KB	Share
BNO	End-of-Treatment Milestone Met in Phase 2 PTSD Trial	PRICE SENSITIVE	09/07/18	110.08KB	Share
BNO	Commencement of BNC210 Phase 2 Agitation Trial	PRICE SENSITIVE	23/05/18	115.67KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/18	204.65KB	Share
BNO	Bionomics Presents BNC101 and BNC105 Data at AACR Conference	PRICE SENSITIVE	13/04/18	178.7KB	Share
BNO	Half Yearly Report and Accounts	PRICE SENSITIVE	14/02/18	862.69KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/18	460.46KB	Share
BNO	Bionomics Receives Over $6.7m R&D Tax Incentive Refund	PRICE SENSITIVE	16/01/18	90.45KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/17	452.51KB	Share
BNO	BNC101 Phase 1 Clinical Trial Recruitment Completed	PRICE SENSITIVE	31/10/17	97.54KB	Share
BNO	Bionomics 2016/2017 Preliminary Final Results	PRICE SENSITIVE	16/08/17	280.54KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/17	394.74KB	Share
BNO	Bionomics Corporate Presentation May 2017	PRICE SENSITIVE	31/05/17	2.03MB	Share
BNO	BNC210 Clinical Data Presented at US Psychiatry Convention	PRICE SENSITIVE	18/05/17	90.6KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	26/04/17	448.72KB	Share
BNO	New BNC105 Clinical Trial in Combination with Keytruda	PRICE SENSITIVE	20/02/17	112.45KB	Share
BNO	Half Yearly Report and Accounts	PRICE SENSITIVE	17/02/17	749.7KB	Share
BNO	MSD Cognition Program Milestone Payment	PRICE SENSITIVE	03/02/17	105.53KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/17	180.15KB	Share
BNO	CEO & Managing Director's Report to Shareholders	PRICE SENSITIVE	08/11/16	637.33KB	Share
BNO	Appendix 4C - quarterly-BNO.AX	PRICE SENSITIVE	31/10/16	984.75KB	Share
BNO	Positive BNC210 Phase 2 Anxiety Trial Results-BNO.AX	PRICE SENSITIVE	21/09/16	107.4KB	Share
BNO	Trading Halt-BNO.AX	PRICE SENSITIVE	19/09/16	98.39KB	Share
BNO	BNC210 Data to be Presented at ECNP-BNO.AX	PRICE SENSITIVE	16/09/16	91.43KB	Share
BNO	Bionomics 2015/2016 Preliminary Final Results-BNO.AX	PRICE SENSITIVE	09/08/16	280.13KB	Share
BNO	Appendix 4C - quarterly-BNO.AX	PRICE SENSITIVE	29/07/16	135.24KB	Share
BNO	BNO To Trial Drug Against Post-Traumatic Stress Disorder-BNO.AX	PRICE SENSITIVE	30/06/16	115.45KB	Share
BNO	Enrolment Completed in Generalised Anxiety Disorder Trial-BNO.AX	PRICE SENSITIVE	24/06/16		Share
BNO	Enrolment Completed in Generalised Anxiety Disorder Trial-BNO.AX	PRICE SENSITIVE	24/06/16	107.44KB	Share
BNO	Bionomics Receives Share of Funds from CTx License Deal-BNO.AX	PRICE SENSITIVE	23/06/16	91.6KB	Share
BNO	Appendix 4C - quarterly-BNO.AX	PRICE SENSITIVE	29/04/16	135.26KB	Share
BNO	BNC105 Cancer Immune Activation Data Presented at AACR-BNO.AX	PRICE SENSITIVE	20/04/16	126.99KB	Share
BNO	Bionomics Initiates Phase 1 Study of BNC101-BNO.AX	PRICE SENSITIVE	04/04/16	136.94KB	Share
BNO	Half Yearly Report and Accounts	PRICE SENSITIVE	18/02/16	3.58MB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/16	135.38KB	Share
BNO	BNC210 Post Traumatic Stress Disorder Trial & Capital Raise	PRICE SENSITIVE	08/12/15	131.17KB	Share
BNO	Trading Halt	PRICE SENSITIVE	04/12/15	98.28KB	Share
BNO	NEW BNC105 DATA TO BE PRESENTED IN U.S.	PRICE SENSITIVE	04/11/15	68.84KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/15	235.84KB	Share
BNO	Merck Investment and Pain Partnership Extended	PRICE SENSITIVE	08/10/15	68.47KB	Share
BNO	BNO Reports Positive Data From BNC210 Clinical Trial	PRICE SENSITIVE	16/09/15	68.72KB	Share
BNO	BNC101 FDA SUBMISSION SUCCESSFUL	PRICE SENSITIVE	31/08/15	65.71KB	Share
BNO	Bionomics 2014/2015 Preliminary Final Results	PRICE SENSITIVE	10/08/15	94.23KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/15	131.66KB	Share
BNO	BNC105 Enhances Efficacy of Immuno-Oncology Therapies	PRICE SENSITIVE	15/06/15	23.09KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/15	131.67KB	Share
BNO	Bionomics Initiates Phase II BNC210 Clinical Trial	PRICE SENSITIVE	20/04/15	54.56KB	Share
BNO	BNC105 NEW DATA	PRICE SENSITIVE	27/02/15	313.59KB	Share
BNO	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/15	837.08KB	Share
BNO	Bionomics Begins Phase 1B Study With Anxiety Drug BNC210	PRICE SENSITIVE	02/02/15	43.59KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/15	98.92KB	Share
BNO	Bionomics To Progress BNC210 In Clinical Trials	PRICE SENSITIVE	11/11/14	43.26KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/14	97.69KB	Share
BNO	BNC105 Data In International Peer-Reviewed Cancer Journal	PRICE SENSITIVE	14/10/14	59.51KB	Share
BNO	BNO Presents BNC105 Phase II Trial Biomarker Data	PRICE SENSITIVE	29/09/14	28.93KB	Share
BNO	Bionomics Acquires Prestwick Chemical	PRICE SENSITIVE	23/09/14	41.93KB	Share
BNO	Bionomics Receives $7.5M 2014 R&D Tax Incentive	PRICE SENSITIVE	05/09/14	37.19KB	Share
BNO	Bionomics 2013/2014 Preliminary Final Results	PRICE SENSITIVE	19/08/14	264.81KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/14	71.63KB	Share
BNO	Bionomics and Merck Enter New Research Collaboration	PRICE SENSITIVE	24/06/14	39.26KB	Share
BNO	Trading Halt	PRICE SENSITIVE	23/06/14	204.66KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/14	36.22KB	Share
BNO	BNC105 Phase II Renal Cancer Trial Results	PRICE SENSITIVE	19/03/14	36.32KB	Share
BNO	Trading Halt	PRICE SENSITIVE	17/03/14	145.06KB	Share
BNO	Bionomics Partner Granted Further $34M in Funding	PRICE SENSITIVE	24/02/14	22.71KB	Share
BNO	Half Yearly Report and Accounts	PRICE SENSITIVE	18/02/14	438.1KB	Share
BNO	BNC105 Achieves High Response Rate in Ovarian Cancer	PRICE SENSITIVE	03/02/14	32.4KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/14	31.76KB	Share
BNO	Bionomics Receives $7.04M 2013 R&D Tax Incentive	PRICE SENSITIVE	18/12/13	22.54KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/13	36.13KB	Share
BNO	Bionomics R&D Tax Incentive For FY2013	PRICE SENSITIVE	08/10/13	22.74KB	Share
BNO	Bionomics 2012/2013 Preliminary Final Results	PRICE SENSITIVE	15/08/13	108.2KB	Share
BNO	Bionomics Signs Option and License Agreement with Merck	PRICE SENSITIVE	31/07/13	21.89KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/13	31.91KB	Share
BNO	Bionomics initiates IND-enabling studies with BNC101	PRICE SENSITIVE	29/07/13	21.51KB	Share
BNO	BNO completes enrolment in Phase II renal cancer trial	PRICE SENSITIVE	11/06/13	30.2KB	Share
BNO	BNC105 Trials Presented at ASCO	PRICE SENSITIVE	03/06/13	29.92KB	Share
BNO	CTX AND BIONOMICS' PROGRAM REACHES KEY MILESTONE	PRICE SENSITIVE	16/05/13	31.3KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/13	37.88KB	Share
BNO	Manufacture of BNC101 commences at Lonza	PRICE SENSITIVE	23/04/13	26.1KB	Share

BNO Appendix 4C - quarterly
30/04/19	PRICE SENSITIVE	344.66KB	Share
BNO S&P DJI Announces March 2019 Quarterly Rebalance
08/03/19	PRICE SENSITIVE	175.31KB	Share
BNO Further Analysis of Phase 2 PTSD Trial Results Presentation
18/02/19	PRICE SENSITIVE	690.3KB	Share
BNO Further Analysis of Phase 2 PTSD Results
18/02/19	PRICE SENSITIVE	136.22KB	Share
BNO Half Yearly Report and Accounts
15/02/19	PRICE SENSITIVE	497.57KB	Share
BNO Appendix 4C - quarterly
31/01/19	PRICE SENSITIVE	369.07KB	Share
BNO BNC105 Clinical Trial In Combination With Nivolumab
04/01/19	PRICE SENSITIVE	142.39KB	Share
BNO Bionomics Receives $650k Licensing Revenue from CTx
21/12/18	PRICE SENSITIVE	77.03KB	Share
BNO Bionomics Receives Over $6.5m R&D Tax Incentive Refund
11/12/18	PRICE SENSITIVE	106.51KB	Share
BNO CEO 2018 AGM Presentation
14/11/18	PRICE SENSITIVE	1.7MB	Share
BNO Executive Chairman 2018 AGM Presentation
14/11/18	PRICE SENSITIVE	532.94KB	Share
BNO FUND RAISING UPDATE
14/11/18	PRICE SENSITIVE	121.77KB	Share
BNO Trading Halt
12/11/18	PRICE SENSITIVE	299.32KB	Share
BNO Recapitalisation by major US-based biotechnology investor
09/11/18	PRICE SENSITIVE	101.83KB	Share
BNO Leadership Changes and Strategic Review
09/11/18	PRICE SENSITIVE	99.71KB	Share
BNO Appendix 4C - quarterly
29/10/18	PRICE SENSITIVE	264.69KB	Share
BNO Bionomics' PTSD Trail Results Presentation
02/10/18	PRICE SENSITIVE	948.2KB	Share
BNO Bionomics' PTSD Trial Results
02/10/18	PRICE SENSITIVE	120.84KB	Share
BNO Trading Halt
28/09/18	PRICE SENSITIVE	135.47KB	Share
BNO Bionomics 2017/2018 Preliminary Final Results
16/08/18	PRICE SENSITIVE	197.44KB	Share
BNO Appendix 4C - quarterly
20/07/18	PRICE SENSITIVE	258.5KB	Share
BNO End-of-Treatment Milestone Met in Phase 2 PTSD Trial
09/07/18	PRICE SENSITIVE	110.08KB	Share
BNO Commencement of BNC210 Phase 2 Agitation Trial
23/05/18	PRICE SENSITIVE	115.67KB	Share
BNO Appendix 4C - quarterly
30/04/18	PRICE SENSITIVE	204.65KB	Share
BNO Bionomics Presents BNC101 and BNC105 Data at AACR Conference
13/04/18	PRICE SENSITIVE	178.7KB	Share
BNO Half Yearly Report and Accounts
14/02/18	PRICE SENSITIVE	862.69KB	Share
BNO Appendix 4C - quarterly
31/01/18	PRICE SENSITIVE	460.46KB	Share
BNO Bionomics Receives Over $6.7m R&D Tax Incentive Refund
16/01/18	PRICE SENSITIVE	90.45KB	Share
BNO Appendix 4C - quarterly
31/10/17	PRICE SENSITIVE	452.51KB	Share
BNO BNC101 Phase 1 Clinical Trial Recruitment Completed
31/10/17	PRICE SENSITIVE	97.54KB	Share
BNO Bionomics 2016/2017 Preliminary Final Results
16/08/17	PRICE SENSITIVE	280.54KB	Share
BNO Appendix 4C - quarterly
27/07/17	PRICE SENSITIVE	394.74KB	Share
BNO Bionomics Corporate Presentation May 2017
31/05/17	PRICE SENSITIVE	2.03MB	Share
BNO BNC210 Clinical Data Presented at US Psychiatry Convention
18/05/17	PRICE SENSITIVE	90.6KB	Share
BNO Appendix 4C - quarterly
26/04/17	PRICE SENSITIVE	448.72KB	Share
BNO New BNC105 Clinical Trial in Combination with Keytruda
20/02/17	PRICE SENSITIVE	112.45KB	Share
BNO Half Yearly Report and Accounts
17/02/17	PRICE SENSITIVE	749.7KB	Share
BNO MSD Cognition Program Milestone Payment
03/02/17	PRICE SENSITIVE	105.53KB	Share
BNO Appendix 4C - quarterly
31/01/17	PRICE SENSITIVE	180.15KB	Share
BNO CEO & Managing Director's Report to Shareholders
08/11/16	PRICE SENSITIVE	637.33KB	Share
BNO Appendix 4C - quarterly-BNO.AX
31/10/16	PRICE SENSITIVE	984.75KB	Share
BNO Positive BNC210 Phase 2 Anxiety Trial Results-BNO.AX
21/09/16	PRICE SENSITIVE	107.4KB	Share
BNO Trading Halt-BNO.AX
19/09/16	PRICE SENSITIVE	98.39KB	Share
BNO BNC210 Data to be Presented at ECNP-BNO.AX
16/09/16	PRICE SENSITIVE	91.43KB	Share
BNO Bionomics 2015/2016 Preliminary Final Results-BNO.AX
09/08/16	PRICE SENSITIVE	280.13KB	Share
BNO Appendix 4C - quarterly-BNO.AX
29/07/16	PRICE SENSITIVE	135.24KB	Share
BNO BNO To Trial Drug Against Post-Traumatic Stress Disorder-BNO.AX
30/06/16	PRICE SENSITIVE	115.45KB	Share
BNO Enrolment Completed in Generalised Anxiety Disorder Trial-BNO.AX
24/06/16	PRICE SENSITIVE		Share
BNO Enrolment Completed in Generalised Anxiety Disorder Trial-BNO.AX
24/06/16	PRICE SENSITIVE	107.44KB	Share
BNO Bionomics Receives Share of Funds from CTx License Deal-BNO.AX
23/06/16	PRICE SENSITIVE	91.6KB	Share
BNO Appendix 4C - quarterly-BNO.AX
29/04/16	PRICE SENSITIVE	135.26KB	Share
BNO BNC105 Cancer Immune Activation Data Presented at AACR-BNO.AX
20/04/16	PRICE SENSITIVE	126.99KB	Share
BNO Bionomics Initiates Phase 1 Study of BNC101-BNO.AX
04/04/16	PRICE SENSITIVE	136.94KB	Share
BNO Half Yearly Report and Accounts
18/02/16	PRICE SENSITIVE	3.58MB	Share
BNO Appendix 4C - quarterly
29/01/16	PRICE SENSITIVE	135.38KB	Share
BNO BNC210 Post Traumatic Stress Disorder Trial & Capital Raise
08/12/15	PRICE SENSITIVE	131.17KB	Share
BNO Trading Halt
04/12/15	PRICE SENSITIVE	98.28KB	Share
BNO NEW BNC105 DATA TO BE PRESENTED IN U.S.
04/11/15	PRICE SENSITIVE	68.84KB	Share
BNO Appendix 4C - quarterly
30/10/15	PRICE SENSITIVE	235.84KB	Share
BNO Merck Investment and Pain Partnership Extended
08/10/15	PRICE SENSITIVE	68.47KB	Share
BNO BNO Reports Positive Data From BNC210 Clinical Trial
16/09/15	PRICE SENSITIVE	68.72KB	Share
BNO BNC101 FDA SUBMISSION SUCCESSFUL
31/08/15	PRICE SENSITIVE	65.71KB	Share
BNO Bionomics 2014/2015 Preliminary Final Results
10/08/15	PRICE SENSITIVE	94.23KB	Share
BNO Appendix 4C - quarterly
31/07/15	PRICE SENSITIVE	131.66KB	Share
BNO BNC105 Enhances Efficacy of Immuno-Oncology Therapies
15/06/15	PRICE SENSITIVE	23.09KB	Share
BNO Appendix 4C - quarterly
30/04/15	PRICE SENSITIVE	131.67KB	Share
BNO Bionomics Initiates Phase II BNC210 Clinical Trial
20/04/15	PRICE SENSITIVE	54.56KB	Share
BNO BNC105 NEW DATA
27/02/15	PRICE SENSITIVE	313.59KB	Share
BNO Half Yearly Report and Accounts
23/02/15	PRICE SENSITIVE	837.08KB	Share
BNO Bionomics Begins Phase 1B Study With Anxiety Drug BNC210
02/02/15	PRICE SENSITIVE	43.59KB	Share
BNO Appendix 4C - quarterly
30/01/15	PRICE SENSITIVE	98.92KB	Share
BNO Bionomics To Progress BNC210 In Clinical Trials
11/11/14	PRICE SENSITIVE	43.26KB	Share
BNO Appendix 4C - quarterly
31/10/14	PRICE SENSITIVE	97.69KB	Share
BNO BNC105 Data In International Peer-Reviewed Cancer Journal
14/10/14	PRICE SENSITIVE	59.51KB	Share
BNO BNO Presents BNC105 Phase II Trial Biomarker Data
29/09/14	PRICE SENSITIVE	28.93KB	Share
BNO Bionomics Acquires Prestwick Chemical
23/09/14	PRICE SENSITIVE	41.93KB	Share
BNO Bionomics Receives $7.5M 2014 R&D Tax Incentive
05/09/14	PRICE SENSITIVE	37.19KB	Share
BNO Bionomics 2013/2014 Preliminary Final Results
19/08/14	PRICE SENSITIVE	264.81KB	Share
BNO Appendix 4C - quarterly
31/07/14	PRICE SENSITIVE	71.63KB	Share
BNO Bionomics and Merck Enter New Research Collaboration
24/06/14	PRICE SENSITIVE	39.26KB	Share
BNO Trading Halt
23/06/14	PRICE SENSITIVE	204.66KB	Share
BNOAppendix 4C - quarterly
30/04/14	PRICE SENSITIVE	36.22KB	Share
BNOBNC105 Phase II Renal Cancer Trial Results
19/03/14	PRICE SENSITIVE	36.32KB	Share
BNOTrading Halt
17/03/14	PRICE SENSITIVE	145.06KB	Share
BNOBionomics Partner Granted Further $34M in Funding
24/02/14	PRICE SENSITIVE	22.71KB	Share
BNOHalf Yearly Report and Accounts
18/02/14	PRICE SENSITIVE	438.1KB	Share
BNOBNC105 Achieves High Response Rate in Ovarian Cancer
03/02/14	PRICE SENSITIVE	32.4KB	Share
BNOAppendix 4C - quarterly
31/01/14	PRICE SENSITIVE	31.76KB	Share
BNOBionomics Receives $7.04M 2013 R&D Tax Incentive
18/12/13	PRICE SENSITIVE	22.54KB	Share
BNOAppendix 4C - quarterly
31/10/13	PRICE SENSITIVE	36.13KB	Share
BNOBionomics R&D Tax Incentive For FY2013
08/10/13	PRICE SENSITIVE	22.74KB	Share
BNOBionomics 2012/2013 Preliminary Final Results
15/08/13	PRICE SENSITIVE	108.2KB	Share
BNOBionomics Signs Option and License Agreement with Merck
31/07/13	PRICE SENSITIVE	21.89KB	Share
BNOAppendix 4C - quarterly
30/07/13	PRICE SENSITIVE	31.91KB	Share
BNOBionomics initiates IND-enabling studies with BNC101
29/07/13	PRICE SENSITIVE	21.51KB	Share
BNOBNO completes enrolment in Phase II renal cancer trial
11/06/13	PRICE SENSITIVE	30.2KB	Share
BNOBNC105 Trials Presented at ASCO
03/06/13	PRICE SENSITIVE	29.92KB	Share
BNOCTX AND BIONOMICS' PROGRAM REACHES KEY MILESTONE
16/05/13	PRICE SENSITIVE	31.3KB	Share
BNOAppendix 4C - quarterly
30/04/13	PRICE SENSITIVE	37.88KB	Share
BNOManufacture of BNC101 commences at Lonza
23/04/13	PRICE SENSITIVE	26.1KB	Share

REFRESH

First 2 3

BIONOMICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Top Stories

Corporate Spotlight
Not Yet Available